18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis

Sponsor
Nanjing First Hospital, Nanjing Medical University
Study ID
NCT06937112
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • PET-CT examination — OTHER
    Intravenous injection of 18F-FAPI-YQ104 for PET-CT examination

Study Details

Evaluate the safety of the novel FAP targeted molecular probe 18F-FAPI-YQ104 labeled with radioactive isotopes in clinical applications and verify its effectiveness in tumor diagnosis.

Key Dates

First listed
Apr 22, 2025
Start date
Apr 10, 2025
Status verified
Apr 2025
Primary completion
Jan 31, 2026
Completion
Mar 31, 2026

Study Design

Enrollment
20 participants (estimated)

Primary Outcome Measure

SUVmax of lesion uptake value [ Time Frame: 60 minutes after administration ]

Central Contacts

Find similar trials

Nationwide
Neuroendocrine tumors trialsPancreatic cancer trialsOncology trialsGI oncology trials

Related Studies